Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial
2023; Elsevier BV; Volume: 12; Issue: 1 Linguagem: Inglês
10.1016/s2213-8587(23)00316-9
ISSN2213-8595
AutoresKausik K. Ray, Stephen J. Nicholls, Na Li, Michael J. Louie, Danielle M. Brennan, A. Michael Lincoff, Steven E. Nissen,
Tópico(s)Cancer, Lipids, and Metabolism
ResumoStatins reduce LDL cholesterol and cardiovascular events among those with or without diabetes but have been reported to increase new-onset diabetes. The CLEAR Outcomes trial demonstrated that bempedoic acid reduced the risk of major adverse cardiovascular events among statin-intolerant patients at high cardiovascular risk. In this prespecified analysis, our dual aims were to evaluate the cardiovascular benefits of bempedoic acid, an ATP-citrate lyase inhibitor, in individuals with diabetes, and to evaluate the risk of new-onset diabetes and HbA
Referência(s)